Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed\* hepatocellular carcinoma
• * Unresectable disease
• * Child's class A or B with liver-predominant and asymptomatic extrahepatic disease NOTE: \*A highly suspicious liver mass on CT scan or MRI in the presence of alpha fetoprotein \> 200 mg/dL may be used as alternative diagnostic criterion
• PATIENT CHARACTERISTICS:
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• Absolute neutrophil count \> 1,500/mm³
• Platelet count \> 50,000/mm³
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 5.0 times upper limit of normal (ULN)
• Bilirubin ≤ 5.0 mg/dL
• Creatinine normal OR creatinine clearance \> 50 mL/min
• No significant traumatic injury within the past 28 days
• No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
• No serious, nonhealing wound, ulcer, or bone fracture
• PRIOR CONCURRENT THERAPY:
• No major surgery or open biopsy within the past 28 days
• No minor surgery (e.g., fine-needle aspirations or core biopsies) within the past 7 days
• No chemotherapy within the past 4 weeks
• No radiotherapy within the past 21 days
• No concurrent major surgery
• No other concurrent chemotherapy
• No other concurrent investigational drugs